腹腔镜保脾脾门淋巴结清扫用于未侵犯胃大弯的局部进展期近端胃癌的随机临床试验
这项开放标签前瞻性随机临床试验纳入536例未侵犯胃大弯的cT2-4a/N0-3/M0局部进展期近端胃癌患者,比较腹腔镜全胃切除联合保脾脾门淋巴结清扫(D2+No.10组)与常规腹腔镜全胃切除(D2组)的疗效。亚组分析提示胃后壁进展期胃癌患者可从脾门淋巴结清扫中获益。
要点
- 保脾脾门淋巴结清扫未显著改善整体3年无病生存率。
- 保脾脾门淋巴结清扫组3年总生存率优于常规D2组。
- 胃后壁进展期胃癌患者可能从脾门淋巴结清扫中获益。
核心结论
- 腹腔镜保脾脾门淋巴结清扫不能显著改善未侵犯胃大弯的局部进展期近端胃癌患者的3年无病生存率,但胃后壁进展期胃癌患者可能获益。
研究设计与样本
- 开放标签前瞻性随机临床试验,2015年1月至2018年10月纳入536例临床分期cT2-4a/N0-3/M0且未侵犯胃大弯的局部进展期近端胃癌患者,最终分析526例,D2+No.10组263例、D2组263例。
主要发现
- D2+No.10组3年总生存率为75.7%(95%CI 70.6-80.8),优于D2组的66.5%(95%CI 60.8-72.2),P=0.02。
- 多因素分析显示脾门淋巴结清扫不是无病生存(HR 0.86,95%CI 0.63-1.16)或总生存(HR 0.81,95%CI 0.59-1.12)的独立保护因素。
- 多因素分析证实胃后壁进展期胃癌患者可从No.10淋巴结清扫获得生存获益(无病生存HR 0.10,95%CI 0.02-0.46;总生存HR 0.12,95%CI 0.03-0.52)。
临床怎么用
- 对于未侵犯胃大弯的局部进展期近端胃癌,保脾脾门淋巴结清扫不应作为常规推荐,但胃后壁进展期胃癌患者可考虑行该清扫以改善生存。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: The survival benefit of laparoscopic total gastrectomy combined with spleen-preserving splenic hilar lymphadenectomy (LSTG) for locally advanced proximal gastric cancer (APGC) without invasion into the greater curvature remains uncertain. OBJECTIVE: To compare the long-term and short-term efficacy of LSTG (D2 + No. 10 group) and conventional laparoscopic total gastrectomy (D2 group) for patients with APGC that has not invaded the greater curvature. DESIGN, SETTING, AND PARTICIPANTS: In this open-label, prospective randomized clinical trial, a total of 536 patients with clinical stage cT2 to 4a/N0 to 3/M0 APGC without invasion into the greater curvature were enrolled from January 2015 to October 2018. The final follow-up was on October 31, 2021. Data were analyzed from December 2021 to February 2022. INTERVENTIONS: Eligible patients were randomized to the D2 + No. 10 group or the D2 group. MAIN OUTCOMES AND MEASURES: The primary outcome was 3-year disease-free survival (DFS). The secondary outcomes were 3-year overall survival (OS) and morbidity and mortality within 30 days after surgery. RESULTS: Of 526 included patients, 392 (74.5%) were men, and the mean (SD) age was 60.6 (9.6) years. A total of 263 patients were included in the D2 + No. 10 group, and 263 were included in the D2 group. The 3-year DFS was 70.3% (95% CI, 64.8-75.8) for the D2 + No. 10 group and 64.3% (95% CI, 58.4-70.2; P = .11) for the D2 group, and the 3-year OS in the D2 + No. 10 group was better than that in the D2 group (75.7% [95% CI, 70.6-80.8] vs 66.5% [95% CI, 60.8-72.2]; P = .02). Multivariate analysis revealed that splenic hilar lymphadenectomy was not an independent protective factor for DFS (hazard ratio [HR], 0.86; 95% CI, 0.63-1.16) or OS (HR, 0.81; 95% CI, 0.59-1.12). Stratification analysis showed that patients with advanced posterior gastric cancer in the D2 + No. 10 group had better 3-year DFS (92.9% vs 39.3%; P < .001) and OS (92.9% vs 42.9%; P < .001) than those in the D2 group. Multivariate analysis confirmed that patients with advanced posterior gastric cancer could have the survival benefit from No. 10 lymph node dissection (DFS: HR, 0.10; 95% CI, 0.02-0.46; OS: HR, 0.12; 95% CI, 0.03-0.52). CONCLUSIONS AND RELEVANCE: Although LSTG could not significantly improve the 3-year DFS of patients with APGC without invasion into the greater curvature, patients with APGC located posterior gastric wall may benefit from LSTG. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02333721.
引用
- Lin JX, Lin JP, Wang ZK, et al. Assessment of Laparoscopic Spleen-Preserving Hilar Lymphadenectomy for Advanced Proximal Gastric Cancer Without Invasion Into the Greater Curvature: A Randomized Clinical Trial. JAMA Surg. 2023. PMID: 36383362. doi:10.1001/jamasurg.2022.5307
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。